The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Serendipity, that's what I thought when I invested here, (then proceed to lose 10K) was that medical insurance would pay the price! But It's not happening.
I also would pay for the PSE test as a choice, rather than have a biopsy, my point was: The average person in a good state of health is not going to pay £750 for the test, they may do, if, after having a cheap PSA test that has flagged up a problem.
I don't know much about medical insurance in america, but I do know if you start making claim on house/car insurance in the UK the price goes up, also something similar with pet insurance, as the dog gets older, the price goes up.
Folk are not going to pay £750 for an annual checkup PSE test, maybe they will pay it if something sinister has been flagged!
Also, over two grand for the CiRT test is a lot of money, seems to me, It's priced to take advantage, bit like the top heavy management running this company.
Jerry Randall was saying in the podcast, the iced cherry flavour mouthwash was selling well, in that case, perhaps they should introduce more flavors just to be different from the rest, like Apple, Strawberry, Blueberry, even bubble gum flavour might sell well.
https://youtu.be/wVVkU9gG_J8
Someone is loading up ahead of next news, volume is much higher than normal.
Two chunky buys reported after the end of play.
With the appointment of joint corporate broker, I do wonder if it has anything to do with being approached with a takeover offer, the cash position is looking good, so can't see extra funds being needed.
Am I right in thinking, the £2.4 million fundraise will be converted into shares at Circa 20% of the current share price.
The Company has raised gross proceeds of £2.4 million through the issue of unsecured convertible notes ("CLNs") convertible into the Company's ordinary shares of 0.01 pence ("Ordinary Shares") at a price of 0.035 pence per share. The CLNs have been placed by Patronus Partners with new and existing investors in the Company.
A 30% increase in profits and a reduction in debt should add up to a 30% increase in share price, at least I would have thought.